drugset
drugset / Trial / NCT02981446

A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT

NCT02981446 ↗

Phase 3 Completed 370 enrolled Santen Pharmaceutical Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to investigate the intraocular pressure-lowering effect and the safety of DE-117 ophthalmic solution compared with Latanoprost ophthalmic solution in subjects with open angle glaucoma or ocular hypertension.

Timeline

Start
2017-01
Primary completion
2019-01
Completion
2019-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Latanoprost ophthalmic solution Unknown 0.005 % Other
Subject omidenepag isopropyl Small molecule 0.002 % Other

Indications

open-angle glaucoma